TIGIT and esophageal squamous cell carcinoma: Ongoing research into predictive biomarkers for anti-TIGIT ICI and the development of anti-TIGIT antibodies with optimal immunologic activity and therapeutic efficacy are critical for advancing TIGIT-targeting therapies in the treatment of ESCC and other cancers.